PubMed Health⌕ Search

PubMed · 17225915

Löffler endocarditis without peripheral eosinophilia.

Abstract

The source did not provide an abstract. Follow the original record for more information.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

G H Wasmeier, D Ropers, A Dimmler, T Fischlein, W G Daniel. 2007-01-22. Löffler endocarditis without peripheral eosinophilia.. https://doi.org/10.1007/s00392-007-0483-2

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Rituximab for treatment of opsoclonus-myoclonus syndrome in neuroblastoma.

Opsoclonus-myoclonus syndrome (OMS) is a rare paraneoplastic syndrome that occurs in 2%-3% of patients with neuroblastoma. The cause of this syndrome is believed to be immune mediated, but the exact mechanism still remains unclear. There is an urgent need to improve our current strategies for treating patients with OMS, as many patients have significant long-term neurologic deficits and behavior disorders with current treatment approaches. Therapies that have shown to improve symptoms in these patients have ranged from ACTH and corticosteroids, to intravenous gammaglobulin and plasmapheresis. We report our experience with Rituximab in a patient with neuroblastoma and OMS.

Adrenal Cortex Hormones↗

Cyclosporine sparing with mycophenolate mofetil, daclizumab and corticosteroids in renal allograft recipients: the CAESAR Study.

Although the calcineurin inhibitors (CNI) cyclosporine (CsA) and tacrolimus are highly effective immunosuppressants, they are associated with serious side effects. There is great interest in immunosuppressive regimens that permit reduction or elimination of CNIs, while maintaining adequate immunosuppression and acceptable acute rejection rates. Patients (n = 536) receiving their first renal allograft were randomized to one of three immunosuppressant regimens: daclizumab, mycophenolate mofetil (MMF), corticosteroids (CS) and low-dose CsA (target trough levels of 50-100 ng/mL), weaned from month 4 and withdrawn by month 6; daclizumab, MMF, CS and low-dose CsA; or MMF, CS and standard-dose CsA. Mean GFR 12 months after transplantation (primary end point) was not statistically different in the CsA withdrawal and low-dose CsA groups (both 50.9 mL/min/1.73 m(2)) vs. the standard-dose CsA group (48.6 mL/min/1.73 m(2)). At 12 months, the incidence of biopsy-proven acute rejection was significantly higher in the CsA withdrawal group (38%) vs. the low- or standard-dose CsA groups (25.4% and 27.5%, respectively; p < 0.05). In summary, a regimen of continuous low-dose CsA with MMF, CS and daclizumab induction is a clinically safe and effective immunosuppressive regimen in renal transplant recipients.

Adrenal Cortex Hormones↗

Analytical methods for the determination of selected steroid sex hormones and corticosteriods in wastewater.

An analytical method for the determination of 12 selected estrogens, progestagens and corticosteroids is presented. The optimization of the method, including liquid chromatography separation, extraction on a solid phase, purification on a silica gel cartridge and detection by mass spectrometry, is described. Both the repeatability, with relative standard deviation ranging from 1.4 to 2.7%, and the accuracy, with recoveries ranging from 92.7 to 102.4%, were very satisfactory for ten of the target analytes. The limits of detection were lower than 1 ng/L for progestagens, androgens and corticosteroids, and ranged between 0.9 and 4.3 ng/L for estrogens. The results of the analysis of two sewage treatment plants in the area of Lyon (France) by this method reveal that all the compounds investigated are present in the effluents. The estrogen most frequently detected was estrone, with a median of 26.1 ng/L. The target progestagens were detected with concentrations ranging between 5 and 41 ng/L. Androgens were also present in most of the samples in the range 1-30 ng/L, while the corticosteroids were present only in one plant, with a median of 31.9 ng/L.

Adrenal Cortex Hormones↗